Cannabis Science Appoints Dr. Mitch Earleywine Renowned Psychology Expert As Its First Member Of Its New Scientific Advisory Board

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB: CBIS) an emerging pharmaceutical cannabis company is pleased and honored to announce that Dr. Mitch Earleywine has accepted its invitation to become the first member of its newly formed Scientific Advisory Board.

Dr. Earleywine is an Associate Professor of Psychology at the State University of New York (SUNY) at Albany. He has received numerous awards for his excellence in teaching and research. Dr. Earleywine has extensive experience in the areas of drug and alcohol abuse, and has published 89 peer reviewed scientific articles, many of which examine marijuana use. Additionally, Dr. Earleywine has authored 5 books including "The Parents Guide to Marijuana." He has professional affiliations with the Association for the Advancement of Behavior Therapy, the Research Society on Alcoholism Member; Dr. Earleywine is on the Advisory Board of the National Organization for the Reform of Marijuana Law (NORML) and is on the Executive Board of the Marijuana Policy Project (MPP).

Dr. Robert Melamede, Cannabis Science Inc.'s President and CEO said, "We are pleased to announce the creation of our Scientific Advisory Board and we are extremely proud that Dr. Earleywine has become its first member. Having someone as widely respected as Dr. Earleywine working with us will help us draw other talented individuals to our team. We are very confident that Dr. Earleywine will help guide Cannabis Science to success in achieving our goal of providing FDA approved cannabis extract-based pharmaceuticals for a number of debilitating illnesses and conditions."

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.